96: Autologous blood stem cell transplantation Regimen related complications and transplant outcome by Kumar, L. et al.
private and public sources, and was unclear in the remaining 3. There
were no randomized controlled trials evaluating auto-HCT in CLL.
Five studies were single-arm trials and 3 were non-randomized trials
with a control arm (autologous vs. allogeneic). Median age for pts
receiving auto-HCT ranged from 45 to 59 years. When allogeneic
HCT was the control arm, the median age ranged from 40 to 47
years. The cumulative number of pts receiving auto-HCT is 403 (M
294, F 109). Primary endpoints in the trials were: CR (clinical or
molecular) 4; OS2; PFS1; engraftment1. Median clinical re-
sponse rates from 6 studies ranged from 54.5 % to 89.4% at 3 to 20
months. Molecular response in one study was 76.9%. Overall survival
at 3 to 6 years in 4 studies were 88.6% to 58%. Median progression-
free survival in 3 studies were 92.3 % at 4 years to 30% at 6 years.
Conclusion: The evidentiary base to recommend HDT and auto-
HCT as standard practice in CLL is limited. Improved response rates,
especially molecular responses are encouraging. It is uncertain
whether auto-HCT is superior to CC as a salvage strategy, but data
appears promising to take it to a formal testing in a randomized study.
Table 1:
Studies identiﬁed in Medline and hand-search of references
(N82)
Not included (N74) [Reviews18, Not clinical outcome17,
not clinical trial13, not transplant trial12, not CLL8, not in
English3, prognostic-marker studies3]
Eligible studies (N8) [single-arm trials5, non-randomized
comparison3]
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Purpose : To determine the transplant related complications
after autologous peripheral blood stem cell transplantation (ASCT)
and overall outcome.
Design : Cohort study of 144 consecutive patients.
Setting : A tertiary care centre
Patients and Methods : 144 consecutive patients (median age 47.5
years, range, 11 to 68 years) underwent ASCT. There were 102 males
and 42 females. Indications for transplant were : multiple myeloma-
78(54.2%), Hodgkin’s-14(9.7%), non Hodgkin’s lymphoma-
14(9.7%), acute leukemia 17, CML -5(3.5%), solid tumours
-16(10.7%). Patients received G-CSF mobilized peripheral blood
stem cells (PBSC). All patients were treated in a single room with
reverse barrier nursing without laminar air ﬂow or HEPA ﬁlter. High
dose (HD) chemotherapy was given using standard protocols . Organ
toxicity was assessed according to Seattle criteria and response to
transplant as per standard guidelines.
Results : 126 of 144 patients engrafted. 19 (13.2%) patients died
prior to day 30. The causes of death were sepsis with or without
multi-organ failure (n-12) and regimen related toxicity-7 (4.2%). Fac-
tors like poor performance status , progressive or refractory disease at
transplant and failure to engraft by day 18 were associated with
increased risk of day 30 mortality. GIT toxicity, mucositis, veno-
occlusive disease, liver and renal dysfunction were main regimen
related toxicities; GIT toxicity and mucositis was signiﬁcantly higher
among patients who received HD melphalan for conditioning. Post
transplant, CR rate was signiﬁcantly higher in chemosensitive disease
group (70%) compared to 20% in chemo-refractory disease, p.01.
The median overall survival (OS) for all patients is 55 months 
9.07(CI 37.22-72.78) with estimated OS at 2 and 5 years being 66.5%
and 45%, respectively. Event - free survival (EFS) for the whole group
is 24 months  5.13(13.94-34.06) with probability of EFS 2 and 5
years being 47.2 %, and 41%, respectively . Survival was signiﬁcantly
better for patients with chemo-sensitive disease at transplant (median
OS 89 months vs 18 months,p.0001). Patients who were in CR post
transplant had a signiﬁcantly better overall survival . Currently, 60 of
126 patients (47.6%) are alive at a median follow up of 3 years. 66
patients have died predominantly due to relapse - 57/66 (86.4%).
Conclusion : Good primary pre-transplant management and
careful case selection are two important factors associated with
good transplant outcome.
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RITUXIMAB-RELATED LATE-ONSET NEUTROPENIA AFTER AUTOLO-
GOUS STEM CELL TRANSPLANTATION FOR MALIGNANT LYMPHOMA
Nagafuji, K.1, Numata, A.1, Yoshimoto, G.1, Harada, N.1,
Harada, M.1 11st Dep of Internal Medicine, Kyushu University Hospi-
tal, Fukuoka, Japan.
Rituximab (Rit) chimeric human/mouse monoclonal antibody
directed against the CD20 antigen. It can be used before stem cell
harvest as a way of in vivo purging or after stem cell transplantation
as an adjuvant therapy.
Recently, several cases of late-onset neutropenia (LON) have
been described in relation to its utilization in stem cell transplan-
tation as well as chemotherapy setting.
The reason why Rit induces neutropenia was poorly understood.
Dunleavy reported that perturbation of SDF-1 during B-cell re-
covery retards neutrophil egress from the bone marrow as a mech-
anism of Rit-induced neutropenia (Blood, Vol. 106, 795-802).
We retrospectively analyzed the incidence of LON in autologous
peripheral blood stem cell transplantation (autoPBSCT) for malig-
nant lymphoma (ML) using Rit, autoPBSCT forMLwithout Rit, and
autoPBSCT of CD34 cells for refractory autoimmune disease (AD).
Methods
LON was deﬁned as neutrophil count less than 1,000/l after
achieving durable hematopoietic engraftment without apparent
reasons including myelotoxic drug, viral infection, or disease pro-
gression. The hematologic data of out patient clinics were retro-
spectively analyzed.
Results
The incidence of LON was 64.3% in autotransplanted ML with
Rit. The Nadir of LON was 69-751 (median 578) /l. The onset
of LON from transplant was 61-128 (median 80) days. The dura-
tion of LON was 14-124 (median 56) days. There were no LON-
related infectious complications.
The incidence of LON of autotransplanted ML without Rit and
autotransplanted AD was 8.3%, and 10%, respectively.
Conclusion When Rit was used peri-autotransplant period, the
incidence of LON was increased. Since autotransplantation with
puriﬁed CD34 cells did not increase the incidence of LON, our
analysis results could not support the idea that perturbation of
SDF-1 during B-cell recovery retards neutrophil egress from the
bone marrow as a mechanism of Rit-induced neutropenia.
Results AD using
CD34
cells
(n10)
ML with Rit
(n14)
ML without Rit
(n12)
age(median) 14-59(54) 31-68(50) 21-63
(54)
sex (M/F) 7 / 7 10 / 2 3 / 7
disease DLBL 12, FL 2 DLBL 6, PTCL
2, LBL 1, MCL
1, 2
SSc 7,
SLE 1,
DM/IP 1,
WG 1
disease status 1CR 11, 1Rel
2, 2CR 1
1CR 8, 1PR 2,
Ref 2
No. of infused
CD34 cells
7.4 (3.9 -13.9)
10e6/kg
8.3 (1.4-24.5)
10e6/kg
4.9 (2.0
-16.0) )
10e6/kg
Conditioning R-MCEC 10,
MCEC 3, 2
MCEC 10, TBI
1, 1
HD-CY
LON 9 (64.3%) 1(8.3%) 1(10%)
Neutoropenia of
known reason
VZV 2 Drug 1 CMV 1
observation period
(median)
121-929 (276) 148-1715 (860)
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